A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in
participants lacking suitable alternative treatment options.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03583164.
An open label, single arm Phase IIb study of olorofim (F901318) in participants with
invasive fungal infections with limited treatment options. Participants received study
treatment for up to 12 weeks in the main phase of the study. At the Investigator's
request and after discussion with the medical monitor, open-label treatment with F901318
could be continued in patients judged by the Investigator to need therapy beyond 84 days
and considered likely to continue to benefit from extended treatment.
Lead OrganizationF2G Biotech GmbH
